南京驯鹿医疗技术有限公司 Mediaroom

IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma

SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 /PRNewswire/ -- IASO Biotechnolog...

2025-11-27 13:44 730

IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea

* Potential new treatment option for multiple myeloma patients in Korea. * Expanded patient acce...

2025-10-29 17:01 806

IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea

Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma

SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 22, 2025 /PRNewswire/ -- IASO Biotherapeutics...

2025-10-22 19:39 1179

$Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma$

Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis

SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 16, 2025 /PRNewswire/ -- IASO Biotherapeutics...

2025-10-16 20:45 1314

Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis

2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment

SHANGHAI, NANJING, China and PLEASANTON, Calif., Sept. 18, 2025 /PRNewswire/ -- IASO Biotherapeutic...

2025-09-19 09:39 1925

2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment

IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

SHANGHAI, NANJING, China and SAN FRANCISCO, July 9, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IAS...

2025-07-09 20:18 2022

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)

SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics (...

2025-06-23 10:01 2126

IASO Bio Receives Orphan Drug Designation from the Saudi Food and Drug Authority for Equecabtagene Autoleucel

SHANGHAI, NANJING, China and SAN FRANCISCO, May 9, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO...

2025-05-09 16:25 2639

IASO Bio Announces Approval of New Drug Application for Equecabtagene Autoleucel by the Macau Pharmaceutical Administration Bureau

SHANGHAI, NANJING, China and SAN JOSE, Calif., March 28, 2025 /PRNewswire/ -- IASO Biotherapeutics ...

2025-03-28 12:55 2139

IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Hong Kong Department of Health

SHANGHAI and NANJING, China and SAN JOSE, Calif., Feb. 14, 2025 /PRNewswire/ -- IASO Biotherapeutic...

2025-02-14 22:30 4334

IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH

SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 9, 2024 /PRNewswire/ -- IASO Biotherapeutics...

2024-12-10 10:00 2262

$IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH$

IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment

SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 30, 2024 /PRNewswire/ -- OnSeptember 23, in...

2024-09-30 13:48 1691

IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment

IASO Bio Presented Comparative Clinical Outcomes on the Optimal Lymphodepletion Prior to Infution of Equecabtagene Autoleucel（FucasoTM）in Patients with Relapsed Refractory Multiple Myeloma at 2024 IMS Annual Meeting

SHANGHAI and NANJING, China and SAN JOSE, Calif, Sept. 29, 2024 /PRNewswire/ -- IASO Biotherapeutic...

2024-09-29 21:00 2866

IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting

SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 27, 2024 /PRNewswire/ -- IASO Biotherapeuti...

2024-09-27 15:41 1731

$IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting$

IASO Bio Receives U.S. FDA Approval of Investigational New Drug Application for Equecabtagene Autoleucel for Two New Autoimmune Disease Indications

SHANGHAI, NANJING, China and SAN JOSE, Calif., Aug. 12, 2024 /PRNewswire/ -- IASO Biotherapeutics (...

2024-08-12 13:52 1995

IASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication -- Systemic Lupus Erythematosus (SLE)

SHANGHAI, NANJING, China and SAN JOSE, Calif. , July 25, 2024 /PRNewswire/ -- IASO Biotechnology (...

2024-07-25 17:46 2568

IASO Bio Receives U.S. FDA Approval of Investigational New Drug Application for Equecabtagene Autoleucel for Multiple Sclerosis

SHANGHAI, NANJING, China and SAN JOSE, Calif., July 23, 2024 /PRNewswire/ -- IASO Biotechnology ("I...

2024-07-24 09:52 2180

IASO Bio and Innovent Enhance Strategic Collaboration in Cell Therapy

SHANGHAI and NANJING, China and SAN JOSE, Calif., July 5, 2024 /PRNewswire/ -- IASO Biotechnology (...

2024-07-05 16:30 4713

IASO Bio Presented Clinical Data and Single-cell Analysis of Equecabtagene Autoleucel for the Treatment of Central Nervous System Autoimmunity in Oral Presentation at EAN Congress 2024

SHANGHAI, NANJING, CHINA, and SAN JOSE, Calif., July 1, 2024 /PRNewswire/ -- IASO biotechnology ("I...

2024-07-01 15:43 1857

Comprehensively Covering Multiple Myeloma: IASO Bio's GPRC5D CAR-T Product RD118 Receives IND Approval from NMPA

NANJING, China, SHANGHAI and SAN JOSE, Calif., June 28, 2024 /PRNewswire/ -- IASO Biotechnology ("I...

2024-06-28 18:59 2523

Latest News